WASHINGTON — Democrats are committed to passing legislation this year to curb prescription drug prices, but they’re still disagreeing on how to cut costs for patients and taxpayers while preserving profits that lure investors to back potentially promising treatments. It boils down to finding a balance: How big a stick should Medicare have to negotiate… Read More »
We all know that the vaccines being delivered around the world right now work by protecting us from getting Covid. But what we still don’t know is whether they’ll also prevent us transmitting the virus to others. We simply don’t have enough public health data to answer the important question of transmission yet. In fact… Read More »
The immuno-oncology data showdown between team Merck and team Bristol Myers Squibb in kidney cancer appears to have a winner in the eyes of at least one analyst. But that doesn’t mean the other party has lost the fight. After last week’s American Society of Clinical Oncology’s Genitourinary Cancers Symposium, Merck and Eisai’s Keytruda-Lenvima combo is the “clear… Read More »